1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Zydus’ Third Quarter Results Met With Mixed Analyst Reactions

As Firm Strikes Fresh Deal With Synthon For 505(b)(2) Product

 
• By Adam Zamecnik

Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.

Zydus lifesciences building, India
Zydus Lifesciences has announced new North American leadership • Source: Shutterstock

Zydus Lifesciences reported a mixed third fiscal quarter, with misses in its domestic Indian business that were offset by growth in the US market where the firm also has multiple opportunities lined up for the near future.

Overall, the firm’s revenue grew by 17% year-over-year to INR 52.7bn ($607.6m), marking a 1% quarter-to-quarter growth. The company reported INR13.9bn in EBITDA, with a margin of 26.3%

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Hikma Eyes $5bn Sales Target As It Sets Out Plans To 2030

 
• By Dave Wallace

Unveiling a new name for its generics business, Hikma has at the same time set out medium-term financial goals for its business that include three-year growth objectives for its sales and profits, as well as aiming at a $5bn turnover target by 2030.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.

Gedeon Richter: General Medicines Unit Deserves ‘More Attention And Credit’

 
• By Dean Rudge

Gedeon Richter’s CEO has urged analysts and the firm itself to give more attention to its “unfairly neglected” General Medicines division – which includes both generics and licensed-in innovative products – during the Hungarian firm’s first-quarter earnings call.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

More from Generics Bulletin